Patient Square Capital LP Allogene Therapeutics, Inc. Transaction History
Patient Square Capital LP
- $277 Billion
- Q2 2025
A detailed history of Patient Square Capital LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Patient Square Capital LP holds 2,635,000 shares of ALLO stock, worth $2.71 Million. This represents 1.07% of its overall portfolio holdings.
Number of Shares
2,635,000
Previous 2,368,186
11.27%
Holding current value
$2.71 Million
Previous $3.46 Billion
13.88%
% of portfolio
1.07%
Previous 1.43%
Shares
3 transactions
Others Institutions Holding ALLO
# of Institutions
169Shares Held
162MCall Options Held
146KPut Options Held
97.1K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$19.3 Million1.28% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$16.9 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA11.2MShares$11.5 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$11.4 Million3.7% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.5MShares$10.8 Million0.5% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $148M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...